Nutriband CEO to Join Nasdaq Life Sciences Advisory Board Biotech Summit
Event summary
- Nutriband CEO Gareth Sheridan to attend the inaugural Nasdaq LaB Biotech Summit on September 16, 2026.
- Summit brings together biotech executives, investors, and industry leaders for networking and thought leadership.
- Nutriband's AVERSA™ technology aims to prevent abuse of transdermal drugs like fentanyl.
- AVERSA™ technology is covered by patents in multiple countries, including the U.S., Europe, and China.
The big picture
Nutriband's participation in the Nasdaq LaB Biotech Summit underscores the growing emphasis on abuse-deterrent technologies in the biotech sector. The event provides a platform for Nutriband to showcase its AVERSA™ technology, which addresses a critical need in the pharmaceutical industry for safer transdermal drug delivery systems. The strategic significance lies in the potential to attract investment and partnerships that can accelerate the commercialization of Nutriband's lead product.
What we're watching
- Technology Validation
- How the exposure at the Nasdaq LaB Biotech Summit will impact the perception and adoption of Nutriband's AVERSA™ technology among investors and industry leaders.
- Regulatory Approval
- The pace at which Nutriband can secure FDA approval and other regulatory clearances for its abuse-deterrent fentanyl patch.
- Market Differentiation
- Whether Nutriband can sustain a competitive edge in the transdermal drug market with its abuse-deterrent technology.
Related topics